Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Clinical and animal model studies have implicated inflammation and peripheral immune cell responses in the pathophysiology of Alzheimer’s disease (AD). Peripheral immune cells including T cells circulate in the cerebrospinal fluid (CSF) of healthy adults and are found in the brains of AD patients and AD rodent models. Blocking entry of peripheral macrophages into the CNS was reported to increase amyloid burden in an AD mouse model. To assess inflammation in the 5xFAD (Tg) mouse model, we first quantified central and immune cell profiles in the deep cervical lymph nodes and spleen. In the brains of Tg mice, activated (MHCII+, CD45high, and Ly6Chigh) myeloid-derived CD11b+ immune cells are decreased while CD3+ T cells are increased as a function of age relative to non-Tg mice. These immunological changes along with evidence of increased mRNA levels for several cytokines suggest that immune regulation and trafficking patterns are altered in Tg mice. Levels of soluble Tumor Necrosis Factor (sTNF) modulate blood-brain barrier (BBB) permeability and are increased in CSF and brain parenchyma post-mortem in AD subjects and Tg mice. We report here that in vivo peripheral administration of XPro1595, a novel biologic that sequesters sTNF into inactive heterotrimers, reduced the age-dependent increase in activated immune cells in Tg mice, while decreasing the overall number of CD4+ T cells. In addition, XPro1595 treatment in vivo rescued impaired long-term potentiation (LTP) measured in brain slices in association with decreased Aβ plaques in the subiculum. Selective targeting of sTNF may modulate brain immune cell infiltration, and prevent or delay neuronal dysfunction in AD. Significance statement Immune cells and cytokines perform specialized functions inside and outside the brain to maintain optimal brain health; but the extent to which their activities change in response to neuronal dysfunction and degeneration is not well understood. Our findings indicate that neutralization of sTNF reduced the age-dependent increase in activated immune cells in Tg mice, while decreasing the overall number of CD4+ Tcells. In addition, impaired long-term potentiation (LTP) was rescued by XPro1595 in association with decreased hippocampal Aβ plaques. Selective targeting of sTNF holds translational potential to modulate brain immune cell infiltration, dampen neuroinflammation, and prevent or delay neuronal dysfunction in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“The pro-inflammatory response of brain-resident immune cells to AD pathophysiology leads to increased local production of cytokines and chemokines, and recruitment of peripheral immune cells (Akiyama et al., 2000; Heneka et al., 2015).”
BackgroundInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 8×
“…expression in 5xFAD mice The 5xFAD (Tg) mouse model of Alzheimer’s disease displays progressive amyloid beta plaque accumulation before 3 months of age, progressive synaptic protein loss as well as later neuronal degeneration, and cognitive deficits by 5 months of age (Oakley et al., 2006).”
BackgroundMethodInfluentialA dural lymphatic vascular system that drains brain interstitial fluid and macromolecules
Aspelund, A., Antila, S., Proulx, S. T., Karlsen, T. V., Karaman, S., Detmar, M., Wiig, H., & Alitalo, K. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142290 · Cited by 2,198
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044 · cited 2×
“MHCII is important for crosstalk between the innate and adaptive immune systems and for presentation of antigens to activate CD4+ T cells (Neefjes et al., 2011).”
BackgroundMethodSystemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“TNF elevations are reported in AD patient plasma, and an acute increase in serum TNF, as well as higher baseline TNF level, has been associated with greater cognitive decline in elderly populations (Holmes et al., 2009; Swardfager et al., 2010).”
BackgroundYang, J., Zhang, L., Yu, C., Yang, X.-F., & Wang, H. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-1 · Cited by 1,099 · cited 1×
“Our data revealed changes in activation status of recruited cells, high expression of Ly6C correlates with expression of CCR2 and higher capacity for phagocytosis while Ly6Clow expression correlates with expression of CX3CR1 and antiinflammatory actions (Yang et al., 2014).”
BackgroundInnate immunity in the central nervous system
Ransohoff, R. M., & Brown, M. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58644 · Cited by 1,034 · cited 1×
“Immune cells, including T cells, neutrophils, and dendritic cells, will traffic to tissues including the brain to conduct immune surveillance and respond to inflammation (Ransohoff and Brown, 2012; Ransohoff and Engelhardt, 2012).”
BackgroundEl Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
TNF receptor subtype signalling: Differences and cellular consequences
MacEwan, D. J. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00262-5 · Cited by 610 · cited 1×
“At the pinnacle of inflammatory cascades, elevations in TNF are associated not only with induction of the inflammatory response but also with chronic inflammation (MacEwan, 2002; Steinman, 2013).”
BackgroundNSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498 · cited 2×
“…pathways in clinical trials has had limited success in slowing cognitive decline, either because the targets are wrong or the intervention too late (McGeer and McGeer, 2007) Yet, global immuno-suppression is not likely to be a viable therapeutic strategy to treat neuroinflammation in AD.”
BackgroundBaruch, K., Rosenzweig, N., Kertser, A., Deczkowska, A., Sharif, A. M., Spinrad, A., Tsitsou-Kampeli, A., Sarel, A., Cahalon, L., & Schwartz, M. (2015) · Nature Communications · doi:10.1038/ncomms8967 · Cited by 491 · cited 2×
“…immune system, via transient depletion or inhibition, increased leukocyte trafficking at the choroid plexus, increased brain CD45highCD11b+ and Treg populations, as well as decreased plaque burden, proinflammatory cytokine mRNA expression, and improved on cognitive function (Baruch et al., 2015).”
BackgroundOccurrence of T cells in the brain of Alzheimer's disease and other neurological diseases
Togo, T., Akiyama, H., Iseki, E., Kondo, H., Ikeda, K., Kato, M., Oda, T., Tsuchiya, K., & Kosaka, K. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00496-9 · Cited by 481 · cited 2×
“T cells are also found in increasing frequency in postmortem brain of aged individuals and patients with AD (Togo et al., 2002).”
BackgroundBrosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8657-1 · Cited by 447
Cunningham, A. J., Murray, C. A., O'Neill, L. A. J., Lynch, M. A., & O'Connor, J. J. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(95)12252-4 · Cited by 433 · cited 19×
“Future studies will be aimed at determining the extent to which the restoration of LTP resulting from sTNF signaling inhibition was due to decreased amyloid Neurobiol Dis.”
InfluentialA novel Ly6C/Ly6G‐based strategy to analyze the mouse splenic myeloid compartment
Rose, S., Misharin, A., & Perlman, H. (2012) · Cytometry Part A · doi:10.1002/cyto.a.22012 · Cited by 347 · cited 6×
“Thus our CD45highCD11b+ population was not purely peripheral macrophages but also contained activated microglia and dendritic cells, which also express CD11b and CD45 at high level; neutrophils were gated out of this population using the marker Ly6G (Rose et al., 2012).”
MethodInfluentialKamphuis, W., Kooijman, L., Schetters, S., Orre, M., & Hol, E. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.007 · Cited by 209 · cited 1×
“CD11c+ microglia that accumulate around amyloid plaques show increased anti-inflammatory genomic expression as compared to CD11c− microglia (Kamphuis et al., 2016).”
BackgroundWlodarczyk, A., Løbner, M., Cédile, O., & Owens, T. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-57 · Cited by 149 · cited 2×
“This population has been shown to expand in response to neuroinflammation and while increasing levels of MHCII equivalent to blood derived CD11c+ cells, express a different cytokine profile (Wlodarczyk et al., 2014).”
BackgroundMechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
Hickman, S. E., & Khoury, J. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011982 · Cited by 120
Varvel, N. H., Grathwohl, S. A., Degenhardt, K., Resch, C., Bosch, A., Jucker, M., & Neher, J. J. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150478 · Cited by 99
Montgomery, S. L., Mastrangelo, M. A., Habib, D., Narrow, W. C., Knowlden, S. A., Wright, T. W., & Bowers, W. J. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.07.001 · Cited by 96
Montgomery, S. L., Narrow, W. C., Mastrangelo, M. A., Olschowka, J. A., O'Banion, M. K., & Bowers, W. J. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.02.030 · Cited by 58 · cited 4×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript hippocampus of 12-month old 3xTg-AD mice (Montgomery et al., 2013), a potentially beneficial response as microglia have a complex role in brain health and disease (Mandrekar-Colucci and Landreth, 2010).”
BackgroundInfluential
Cited by
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Self-citationPeripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
Bettcher, B. M., Tansey, M. G., Dorothée, G., & Heneka, M. T. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00549-x · Cited by 427
Self-citationApoptotic cell death in disease—Current understanding of the NCCD 2023
Vitale, I., Pietrocola, F., Guilbaud, E., Aaronson, S. A., Abrams, J. M., Adam, D., Agostini, M., Agostinis, P., Alnemri, E. S., Altucci, L., et al. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01153-w · Cited by 361
A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease
Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00456 · Cited by 360
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
Metadata
- Authors
- MacPherson, K. P., Sompol, P., Kannarkat, G. T., Chang, J., Sniffen, L., Wildner, M. E., Norris, C. M., & Tansey, M. G.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 102
- Pages
- 81-95
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2590492263
- Cited by
- 158
- References
- 24
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.